Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 31/Aug 00:00
CellProthera shares US regulatory progress of ProtheraCytes cell therapy programme
CellProthera, a regenerative cell therapy developer specialising in ischemic diseases, announced alignment with regulators on a planned pivotal phase III trial design for its ProtheraCytes cell therapy following
Articles similaires
FCMB commends CBN, SEC, NGX Group over successful capital raise
worldstagenews.com - 09/Sep 21:52
WorldStage Newsonline– FCMB Group Plc has lauded key financial regulators, as well as the Nigerian Exchange Group (NGX Group) following the...
FCMB commends CBN, SEC, NGX Group over successful capital raise
worldstagenews.com - 09/Sep 21:52
WorldStage Newsonline– FCMB Group Plc has lauded key financial regulators, as well as the Nigerian Exchange Group (NGX Group) following the...
First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA in mIDH1 AML
drugs.com - 06/Sep 07:09
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024. Rigel Pharmaceuticals, a commercial stage biotechnology company focused on hematologic disorders and...
Research shows potential for a new “off-the-shelf” cell-based therapy for tissue healing
aumanufacturing.com.au - 23:38
Researchers from Monash University, led by Associate Professor Mikaël Martino from the university’s Australian Regenerative Medical Research...
Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases
pharmabiz.com - 05/Sep 00:00
Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...
Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases
pharmabiz.com - 05/Sep 00:00
Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...
Pharvaris provides business update and expands development program for deucrictibant
haei.org - 05/Sep 18:44
Pharvaris provides business update and expands development program for deucrictibant Pharvaris today announced: The planned initiation of CHAPTER-3,...
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Les derniers communiqués
-
Aucun élément